甲非明误用:新出现的挑战和米氮平的潜在作用——一个病例报告。

IF 1.1 4区 医学 Q3 SUBSTANCE ABUSE
Reshma Dcruz, Aravind Karunakaran, Aparna Sasikumar, Sandeep Alex, Smitha Ramadas
{"title":"甲非明误用:新出现的挑战和米氮平的潜在作用——一个病例报告。","authors":"Reshma Dcruz, Aravind Karunakaran, Aparna Sasikumar, Sandeep Alex, Smitha Ramadas","doi":"10.1080/10550887.2025.2514287","DOIUrl":null,"url":null,"abstract":"<p><p>Mephentermine is a sympathomimetic amine with structural and pharmacological similarities to amphetamines. Despite its increasing misuse, particularly among athletes and bodybuilders, there is limited literature on its management. No pharmacological treatments have been approved for mephentermine misuse. We describe two cases of young adult males presenting with symptoms of mephentermine withdrawal, including insomnia, anxiety, and craving. Both had histories of prolonged intravenous mephentermine use, with one managed on an outpatient basis and the other as an inpatient. Mirtazapine was initiated in both cases and was associated with improvements in sleep, anxiety, craving and hyperarousal. Psychotic symptoms in one patient resolved with short-term risperidone. Both patients received brief motivational enhancement therapy and remained abstinent from all substances except tobacco during two months of follow-up. These cases highlight the potential utility of mirtazapine in managing mephentermine misuse, particularly for addressing withdrawal symptoms and craving. Given its noradrenergic and serotonergic profile and its demonstrated efficacy in methamphetamine use, mirtazapine may be a promising candidate for treatment. However, the findings are limited by the case series design and larger, controlled studies are needed to confirm its role in clinical management.</p>","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-6"},"PeriodicalIF":1.1000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mephentermine misuse: an emerging challenge and the potential role of mirtazapine-a case report.\",\"authors\":\"Reshma Dcruz, Aravind Karunakaran, Aparna Sasikumar, Sandeep Alex, Smitha Ramadas\",\"doi\":\"10.1080/10550887.2025.2514287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mephentermine is a sympathomimetic amine with structural and pharmacological similarities to amphetamines. Despite its increasing misuse, particularly among athletes and bodybuilders, there is limited literature on its management. No pharmacological treatments have been approved for mephentermine misuse. We describe two cases of young adult males presenting with symptoms of mephentermine withdrawal, including insomnia, anxiety, and craving. Both had histories of prolonged intravenous mephentermine use, with one managed on an outpatient basis and the other as an inpatient. Mirtazapine was initiated in both cases and was associated with improvements in sleep, anxiety, craving and hyperarousal. Psychotic symptoms in one patient resolved with short-term risperidone. Both patients received brief motivational enhancement therapy and remained abstinent from all substances except tobacco during two months of follow-up. These cases highlight the potential utility of mirtazapine in managing mephentermine misuse, particularly for addressing withdrawal symptoms and craving. Given its noradrenergic and serotonergic profile and its demonstrated efficacy in methamphetamine use, mirtazapine may be a promising candidate for treatment. However, the findings are limited by the case series design and larger, controlled studies are needed to confirm its role in clinical management.</p>\",\"PeriodicalId\":47493,\"journal\":{\"name\":\"Journal of Addictive Diseases\",\"volume\":\" \",\"pages\":\"1-6\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Addictive Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10550887.2025.2514287\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addictive Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10550887.2025.2514287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

摘要

甲非特明是一种与安非他明结构和药理相似的拟交感神经胺。尽管越来越多的人滥用它,尤其是在运动员和健美运动员中,但关于它的管理的文献有限。目前还没有药物疗法被批准用于治疗甲基苯丙胺类药物滥用。我们描述了两例年轻的成年男性,表现出甲非明戒断症状,包括失眠、焦虑和渴望。两人都有长期静脉注射甲苯二胺的历史,其中一人在门诊治疗,另一人住院治疗。在这两种情况下都开始使用米氮平,并与睡眠、焦虑、渴望和过度觉醒的改善有关。1例患者使用短期利培酮后精神病症状得到缓解。两名患者都接受了简短的动机增强治疗,并在两个月的随访中保持除烟草外的所有物质的戒断。这些病例强调了米氮平在处理甲氧胺滥用方面的潜在效用,特别是在解决戒断症状和渴望方面。考虑到米氮平的去甲肾上腺素能和血清素能特征及其在甲基苯丙胺使用中的有效性,米氮平可能是一种有希望的治疗候选者。然而,研究结果受到病例系列设计的限制,需要更大规模的对照研究来证实其在临床管理中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mephentermine misuse: an emerging challenge and the potential role of mirtazapine-a case report.

Mephentermine is a sympathomimetic amine with structural and pharmacological similarities to amphetamines. Despite its increasing misuse, particularly among athletes and bodybuilders, there is limited literature on its management. No pharmacological treatments have been approved for mephentermine misuse. We describe two cases of young adult males presenting with symptoms of mephentermine withdrawal, including insomnia, anxiety, and craving. Both had histories of prolonged intravenous mephentermine use, with one managed on an outpatient basis and the other as an inpatient. Mirtazapine was initiated in both cases and was associated with improvements in sleep, anxiety, craving and hyperarousal. Psychotic symptoms in one patient resolved with short-term risperidone. Both patients received brief motivational enhancement therapy and remained abstinent from all substances except tobacco during two months of follow-up. These cases highlight the potential utility of mirtazapine in managing mephentermine misuse, particularly for addressing withdrawal symptoms and craving. Given its noradrenergic and serotonergic profile and its demonstrated efficacy in methamphetamine use, mirtazapine may be a promising candidate for treatment. However, the findings are limited by the case series design and larger, controlled studies are needed to confirm its role in clinical management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
4.30%
发文量
69
期刊介绍: The Journal of Addictive Diseases is an essential, comprehensive resource covering the full range of addictions for today"s addiction professional. This in-depth, practical journal helps you stay on top of the vital issues and the clinical skills necessary to ensure effective practice. The latest research, treatments, and public policy issues in addiction medicine are presented in a fully integrated, multi-specialty perspective. Top researchers and respected leaders in addiction issues share their knowledge and insights to keep you up-to-date on the most important research and practical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信